Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-Fluorouracil/Leucovorin Clear all
Recruiting Phase 2 Interventional

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

NCT07042685
View directory record Official record
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
Fruquintinib Combined With Chemotherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

NCT01498289
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
Interventions
FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
508
States / cities
Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Molecularly Tailored Therapy for Pancreas Cancer

NCT01888978
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gem-OX, Gem-5FU, Gem-Tax, Modified FOLFOX-6, Ox-Tax, FOLFIRI, Tax-Iri
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Olney, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 7, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

NCT00040391
View directory record Official record
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
28
States / cities
Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 7, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis

NCT00352755
View directory record Official record
Conditions
Peritoneal Neoplasms
Interventions
Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 7, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

NCT06941857
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Folinic Acid, 5-Fluorouracil (5-FU), NC410, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

NCT01124630
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CS-1008, FOLFIRI
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00139230
View directory record Official record
Conditions
Squamous Cell Carcinoma, Carcinoma of Head/Neck
Interventions
Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin, G-CSF, Ciprofloxacin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

NCT00060411
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 7, 2026, 5:15 AM EDT
Not listed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

NCT02839343
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions
radiation therapy, surgery, mFOLFIRINOX, FOLFOX
Radiation · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
154
States / cities
Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 7, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

NCT06821997
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Sucrosofate, Leucovorin Calcium, Oxaliplatin, Surgical Procedure
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

NCT00070122
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 7, 2026, 5:15 AM EDT
Not listed Phase 2 Interventional

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

NCT04672005
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Drug
Lead sponsor
Lyudmyla Berim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 7, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Folfox+Irinotecan+Chemort In Esophageal Cancer

NCT04656041
View directory record Official record
Conditions
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Interventions
FOLFOX/ nal-IRI, Paclitaxel, Carboplatin, Proton Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

NCT00019513
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02588105
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 7, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

NCT01959139
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
154
States / cities
Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 7, 2026, 5:15 AM EDT
Terminated Early Phase 1 Interventional

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

NCT03600623
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
Interventions
Folfirinox, Gemcitabine nab-Paclitaxel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 7, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

NCT04329494
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Duarte, California • Jacksonville, Florida • Greenlawn, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

NCT03483038
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, FOLFOX regimen
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Orlando, Florida • Tallahassee, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

NCT00932438
View directory record Official record
Conditions
Colon Cancer With Metastases to the Liver
Interventions
LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, Bevacizumab
Device · Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Huntsville, Alabama • Sacramento, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

NCT01715233
View directory record Official record
Conditions
Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 7, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors

NCT00001579
View directory record Official record
Conditions
Lymphoma, Neoplasms
Interventions
5-Fluorouracil, Ethynyluracil, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2006 · Synced Oct 7, 2026, 5:15 AM EDT